Clinical Observation On The Treatment Of Elderly Chronic Heart Failure With Frailty Syndrome(Heart And Kidney Yang Deficiency Syndrome) With Shenfu Jianxin Capsule

Objective:To look into the clinical efficacy of Shenfu Jianxin Capsule for the treatment of senile heart failure with frailty syndrome(heart and kidney yang deficiency syndrome).Methods:The control and treatment groups,each with 36 cases,were allocated randomly to 72 patients who met the inclusion criteria diagnosed senile chronic heart failure with frailty syndrome(heart and kidney yang deficient syndrome).The Shenfu Jianxin Capsule(4 capsules)taken orally three times per day for two weeks was given to the treatment group in alongside the conventional western therapy for chronic heart failure that was given to the control group.The two groups of patients had their cardiac function graded before and after treatment,as well as their 6-minute walking distance,Minnesota Heart Failure Quality of Life Scale(MLHFQ),Fried Weakness Assessment Scale score,left ventricular ejection fraction(LVEF),and serum N-terminal B-type natriuretic peptide(NT-pro BNP)levels assessed.Results1.In the therapy group,the overall rates of cardiac function efficacy and the TCM evidence score were 87.50% and 84.38%,respectively,while they were 71.88%and 65.62% in the control group.For the therapy group,this difference between the two groups was statistically significant P<0.01).2.Patients in the two groups had clearly lower MLHFQ scores and serum NT-pro BNP levels after treatment(P<0.01)than they had before.It was clear that perhaps the therapy group’s MLHFQ score and serum NT-pro BNP levels were lower than those of the control group(P<0.01).The therapy group’s 6-minute walking distance was substantially longer than the control group’s(P<0.01)(6-minute walking distance).In the two groups,there was no discernible change in left ventricular ejection fraction(LVEF)(P>0.05).3.After treatment,the Center for Epidemiology Depression Scale(CES-D)score and the time of physical activity(MLTA)in the Fried scale were obviously increased(P<0.01),while the 4.5 meter walking time and the score were obviously decreased(P<0.01).The therapy group’s MLTA was obviously higher than the control group’s,and the walking time of 4.5 meters was obviously lower than the control group’s.After medication,there was no discernible difference between the two groups in terms of grip strength or CES-D scores(P>0.05).Between the two groups’ pre-and post-treatment body weights,there was no discernible difference(P>0.05).Conclusion:Shenfu Jianxin Capsules can improve the clinical symptoms,cardiac function,weakening status and quality of life of elderly patients with chronic heart failure with frailty syndrome(heart and kidney yang deficiency syndrome).